AFP Podcast: Episode 248 – February 2026 (Part 2)

American Family Physician Podcast (AAFP)
Date: February 27, 2026
Facilitators: Dr. Steve Brown, Dr. Elena Kelly, Dr. Chisung Okuagu
Theme: Succinct, evidence-based updates on clinical guidelines and management strategies in family medicine, focusing this episode on obesity medications, cervical cancer screening, tinnitus, low back pain, impetigo, and the impact of CT scans on lifetime cancer risk.

Main Episode Overview

This episode delivers key clinical pearls from the February 2026 issue of American Family Physician. Each topic highlights recent evidence, practical decision-making for family physicians, and mental shifts towards more patient-centered and harm-reducing care, aiming to help busy clinicians stay up to date on best practices.

Key Discussion Points & Segment Summaries

1. Long-Term Use of Obesity Management Medications

[01:30–03:26]

• Modern anti-obesity medications, notably GLP-1 receptor agonists (liraglutide, semaglutide) and dual agonist tirzepatide, are highly effective but have substantial first-year discontinuation rates (~65%), due to cost, side effects, and muscle mass loss.
• Lean Mass Loss: Up to 40% of lost weight may be lean muscle, with regained weight typically being fat, which can exacerbate cardiovascular risks.
• Discontinuation Strategies:
  • Dose De-Escalation: Gradual dose reduction; preliminary data supports better sustained weight loss vs abrupt stop.
  • Interval Dosing: Extending intervals between doses (e.g., from every 10–15 days to 21 days).
  • Add-On Approach: Transitioning to oral obesity meds (e.g., phentermine, topiramate, bupropion/naltrexone) during step-down.
• Lifestyle Commitment: Emphasized as crucial for maintaining weight loss after medication withdrawal.

"Any discontinuation strategy must be paired with a renewed commitment to lifestyle modification." – Chisung Okuagu [03:18]

2. Cervical Cancer Screening – Updated Guidelines

[03:33–07:54]

• Trend towards risk-based screening, with greater use of HPV-based strategies.
• USPSTF 2024 Draft:
  • Ages 21–29: Cytology alone every 3 years.
  • Ages 30–65: Primary HPV testing every 5 years; co-testing and cytology alone remain options when HPV testing is inaccessible.
• Self-Collection Approved (FDA, May 2024): Allows patients to self-swab every 3 years, addressing access and trauma, and enhancing inclusivity for marginalized groups.

"Self-collection has been a game changer in helping clinicians provide care for patients with a history of trauma, are gender or sexual minority, or experience severe discomfort with pelvic examination." – Elena Kelly [04:38]

• American Cancer Society: Prefers primary HPV screening for average risk ages 25–65; facilitates reduced testing, fewer colposcopies.
• Clinical Pitfalls:
  • Over-screening older adults (>65) or those post-hysterectomy for benign reasons has no clinical benefit and adds harm/cost.
  • Primary HPV testing should continue for those with previous CIN2 within 25 years, even post-hysterectomy.
• Managing Abnormal Results:
  • Not all require immediate colposcopy; low-risk can be monitored.
  • ASCCP Risk Calculators recommended for management.
• Special Populations: Immunocompromised patients and those pregnant may need individualized screening plans.
• Harms of Screening: Physical (pain/bleeding), psychological (anxiety, stigma), and systemic (cost, disruption).
• Equity Emphasis: Screening disparities reflect broader reproductive healthcare inequities.

"Using evidence-based guidelines for cervical cancer screening ... helps us as clinicians provide better patient centered care and reduce harmful practices." – Chisung Okuagu [07:54]

3. Management of Tinnitus – VA/DoD Guidelines

[08:06–09:49]

• Bottom Line:
  • Education, therapeutic sound, cognitive behavioral therapy (CBT), and hearing aids/cochlear implants for those with hearing loss are beneficial.
• Education/Counseling: Discuss expectations, association with hearing loss, and the value of hearing protection.
• Therapeutic Sound: Devices (tabletop sound spas/ear-level apps) can lessen tinnitus-related impairment.
• CBT: Evidence-backed, especially in conjunction with sound therapy.
• Not Recommended/Insufficient Evidence:
  • Neurostimulation, acupuncture, low-level laser therapy, and pharmaceuticals.
• Assessment Tool: Use self-report instruments like the Tinnitus Functional Index to guide care.

"No medication, interestingly enough, has been proven beneficial." – Steve Brown [09:30]

4. Non-Pharmacologic & Non-Surgical Low Back Pain Treatment

[10:34–12:37]

• Cochrane Review: 31 systematic reviews, 97,000+ patients with non-specific low back pain (LBP).
• Acute LBP: Continued activity improves outcomes versus rest; spinal manipulation and traction not superior to placebo.
• Chronic LBP: Exercise and multidisciplinary strategies (physical plus psychological therapies) reduce pain and improve function.
  • Acupuncture shows moderate benefit; psychological therapies reduce pain (limited evidence for improved function).
• Safety: Non-pharmacologic approaches generally safe but data on rare/serious adverse events is limited.
• Practice Pearl: Start with non-pharmacologic options before moving to meds or procedures, aligning with major guidelines.

"A good take home message is to start with non pharmacologic options for non specific low back pain ... before reaching for medications or procedures." – Elena Kelly [12:18]

5. Impetigo – Rapid Evidence Review

[12:37–15:47]

• Epidemiology: Superficial bacterial infection (usually Group A strep or S. aureus) especially in children 2–5 years, but also affects older adults.
• Risk Factors: Skin barrier disruption; warm, humid environments; poor hygiene; crowded living.
• Clinical Features: Red papules → fragile vesicles/pustules → honey-colored crusts (classic for non-bullous impetigo).
  • Non-bullous forms predominate in the US (~70%).
• Diagnosis: Clinical; no labs unless diagnosis is unclear or treatment fails.
• Management:
  • Non-severe: Topical antibiotics (mupirocin 2% or retapamulin 1%) BID for 5 days preferred (per 2022 evidence and IDSA).
  • Severe/Widespread/No improvement: Oral antibiotics—narrow spectrum for 7–10 days (cephalexin, dicloxacillin; MRSA suspect: doxycycline, clindamycin, TMP-SMX).
  • Supportive Care: Gentle cleansing; avoid antiseptics (can irritate); promote hygiene; can return to school/work 12–24h after antibiotics or improvement.

"Most non-severe cases can be treated with topical mupirocin for five days." – Elena Kelly [15:47]

6. CT Scans and Projected Lifetime Cancer Risk – POEM

[15:58–17:47]

• Clinical Question: What is the impact of cumulative medical radiation from CT scans?
• Background:
  • CT delivers ionizing radiation, which, over a lifespan, may slightly increase cancer risk—especially leukemia, lung, colon, bladder.
  • ~61.5 million patients in the US had a CT in 2023; 4% were children (who have higher lifetime risk).
• Modeling Estimate: With current trends, up to 103,000 radiation-induced cancers are projected, possibly constituting up to 5% of all new cancers.

"With great power comes great responsibility." – Chisung Okuagu [16:27]

• Clinical Implication: Order CTs judiciously, focusing on scenarios where they truly impact management; avoid unnecessary repeat imaging.

Notable Quotes & Memorable Moments

• "[Self-collection] has been a game changer in helping clinicians provide care for patients with a history of trauma, are gender or sexual minority, or experience severe discomfort with pelvic examination." – Elena Kelly [04:38]
• "The headline isn't CT scans are bad. It's CT scans are powerful, and with great power comes great responsibility." – Chisung Okuagu [16:27]
• "Any discontinuation strategy must be paired with a renewed commitment to lifestyle modification, including exercise and healthy food intake." – Chisung Okuagu [03:18]
• "Bottom line: Impetigo is common, especially in kids ages 2 to 5, diagnosed clinically, and most non-severe cases can be treated with topical mupirocin for five days." – Elena Kelly [15:47]
• "A good take home message is to start with non pharmacologic options for non specific low back pain such as exercise and multidisciplinary care before reaching for medications or procedures." – Elena Kelly [12:18]

Key Timestamps

• 00:32 – Episode introduction and overview
• 01:30 – Long-term obesity management medications
• 03:33 – Cervical cancer screening: updates & controversies
• 08:06 – Management of tinnitus: VA/DoD guidelines
• 10:34 – Non-pharmacologic/non-surgical low back pain care
• 12:37 – Impetigo evidence review and management
• 15:58 – Lifetime cancer risk from CT scans

Tone & Language

The episode maintains a friendly, collegial, and accessible tone, mixing evidence-based discussion with a dose of humor and practical wisdom. The co-hosts keep the content fast-paced but thorough, offering memorable phrasing, clinical anecdotes, and clear bottom-line takeaways without jargon overload.

Takeaways for Listeners

• Modern obesity medications require individualized discontinuation plans and a renewed focus on lifestyle.
• Cervical cancer screening is moving towards risk-based, HPV-focused approaches—self-swabbing is now an option.
• Tinnitus care should center on education, sound therapy, and CBT; avoid unproven interventions.
• For non-specific low back pain, non-pharmacologic management is effective and aligns with best-practice guidelines.
• Impetigo is best treated with topical antibiotics unless severe; diagnosis is mainly clinical.
• CT scanning contributes to cancer risk—a reminder of the need for stewardship and justification for imaging orders.

Listeners walk away with concise, actionable insights supported by recent guidelines—ideal for busy clinicians aiming to deliver updated, patient-centered care.